1
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013.PubMed/NCBI View Article : Google Scholar
|
2
|
Bearfoot JL, Choong DY, Gorringe KL and
Campbell IG: Genetic analysis of cancer-implicated MicroRNA in
ovarian cancer. Clin Cancer Res. 14:7246–7250. 2008.PubMed/NCBI View Article : Google Scholar
|
3
|
Dahiya N, Sherman-Baust CA, Wang TL,
Davidson B, Shih IeM, Zhang Y, Wood W III, Becker KG and Morin PJ:
MicroRNA expression and identification of putative miRNA targets in
ovarian cancer. PLoS One. 3(e2436)2008.PubMed/NCBI View Article : Google Scholar
|
4
|
Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M,
Li X and Tang H: MicroRNA-9 inhibits ovarian cancer cell growth
through regulation of NF-kappaB1. FEBS J. 276:5537–5546.
2009.PubMed/NCBI View Article : Google Scholar
|
5
|
Lu L, Schwartz P, Scarampi L, Rutherford
T, Canuto EM, Yu H and Katsaros D: MicroRNA let-7a: A potential
marker for selection of paclitaxel in ovarian cancer management.
Gynecol Oncol. 122:366–371. 2011.PubMed/NCBI View Article : Google Scholar
|
6
|
Poy MN, Eliasson L, Krutzfeldt J, Kuwajima
S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P
and Stoffel M: A pancreatic islet-specifc microRNA regulates
insulin secretion. Nature. 432:226–230. 2004.PubMed/NCBI View Article : Google Scholar
|
7
|
Wang Q, Liu N, Yang X, Tu L and Zhang X:
Small RNA-mediated responses to low- and high-temperature stresses
in cotton. Sci Rep. 6:35558–35571. 2016.PubMed/NCBI View Article : Google Scholar
|
8
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005.PubMed/NCBI View Article : Google Scholar
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
10
|
Wang Y, Chen F, Zhao M, Yang Z, Zhang S,
Ye L, Gao H and Zhang X: MiR-107 suppresses proliferation of
hepatoma cells through targeting HMGA2 mRNA 3'UTR. Biochem Biophys
Res Commun. 480:455–460. 2016.PubMed/NCBI View Article : Google Scholar
|
11
|
Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang
JR, Han XJ, Zhu SJ, Wang SM, Li YH and Zhang W: miR-10b exerts
oncogenic activity in human hepatocellular carcinoma cells by
targeting expression of CUB and sushi multiple domains 1 (CSMD1).
BMC Cancer. 16(806)2016.PubMed/NCBI View Article : Google Scholar
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View
Article : Google Scholar
|
13
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005.PubMed/NCBI View Article : Google Scholar
|
14
|
Wei J, Zhang L, Li J, Zhu S, Tai M, Mason
CW, Chapman JA, Reynolds EA, Weiner CP and Zhou HH: MicroRNA-205
promotes cell invasion by repressing TCF21 in human ovarian cancer.
J Ovarian Res. 10(33)2017.PubMed/NCBI View Article : Google Scholar
|
15
|
Xie HH, Huan WT, Han JQ, Ren WR and Yang
LH: MicroRNA-663 facilitates the growth, migration and invasion of
ovarian cancer cell by inhibiting TUSC2. Biol Res. 52:18–27.
2019.PubMed/NCBI View Article : Google Scholar
|
16
|
Cui W, Li Y, Xu K, Chen G, Lu X, Duan Q
and Kang Z: miR-361-5p inhibits hepatocellular carcinoma cell
proliferation and invasion by targeting VEGFA. Biochem Biophys Res
Commun. 479:901–906. 2016.PubMed/NCBI View Article : Google Scholar
|
17
|
Ma F, Zhang L, Ma L, Zhang Y, Zhang J and
Guo B: MiR-361-5p inhibits glycolytic metabolism, proliferation and
invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin
Cancer Res. 36(158)2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Chen SF, Liu Z, Chaurasiya S, Dellinger
TH, Lu J, Wu X, Qin H, Wang J, Fong Y and Yuan YC: Identification
of core aberrantly expressed microRNAs in serous ovarian carcinoma.
Oncotarget. 9:20451–20466. 2018.PubMed/NCBI View Article : Google Scholar
|
19
|
Ma J, Jing XT, Chen Z, Duan Z and Zhang Y:
MiR-361-5p decreases the tumorigenicity of epithelial ovarian
cancer cells by targeting at RPL22L1 and c-Met signaling. Int J
Clin Exp Pathol. 11:2588–2596. 2018.PubMed/NCBI
|
20
|
Häcker H, Tseng PH and Karin M: Expanding
TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev
Immunol. 11:457–468. 2011.PubMed/NCBI View
Article : Google Scholar
|
21
|
Yi Z, Lin WW, Stunz LL and Bishop GA:
Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte
functions. Cytokine Growth Factor Rev. 25:147–156. 2014.PubMed/NCBI View Article : Google Scholar
|
22
|
Gong J, Li ZZ, Guo S, Zhang XJ, Zhang P,
Zhao GN, Gao L, Zhang Y, Zheng A, Zhang XF, et al: Neuron-specifc
tumor necrosis factor receptor-associated factor 3 is a central
regulator of neuronal death in acute ischemic stroke. Hypertension.
66:604–616. 2015.PubMed/NCBI View Article : Google Scholar
|
23
|
Zhu CL and Gao GS: MiR-200a overexpression
in advanced ovarian carcinomas as a prognostic indicator. Asian Pac
J Cancer Prev. 15:8595–8601. 2014.PubMed/NCBI View Article : Google Scholar
|
24
|
Zhu L and Fang J: The structure and
clinical roles of MicroRNA in colorectal cancer. Gastroenterol Res
Pract. 2016(1360348)2016.PubMed/NCBI View Article : Google Scholar
|
25
|
Shukla KK, Misra S, Pareek P, Mishra V,
Singhal B and Sharma P: Recent scenario of microRNA as diagnostic
and prognostic biomarkers of prostate cancer. Urol Oncol.
35:92–101. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
Shah MY, Ferrajoli A, Sood AK,
Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an
emerging concept. EBioMedicine. 12:34–42. 2016.PubMed/NCBI View Article : Google Scholar
|
27
|
Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y,
Fang Y, Lin X, Xu Y, Xu W, et al: miR-145 sensitizes ovarian cancer
cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer.
135:1286–1296. 2014.PubMed/NCBI View Article : Google Scholar
|
28
|
Gadducci A, Sergiampietri C, Lanfredini N
and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and
perspectives of clinical research. Gynecol Endocrinol. 30:266–271.
2014.PubMed/NCBI View Article : Google Scholar
|
29
|
Salem M, Shan Y, Bernaudo S and Peng C:
miR-590-3p targets cyclin G2 and FOXO3 to promote ovarian cancer
cell proliferation, invasion, and spheroid formation. Int J Mol
Sci. 20(E1810)2019.PubMed/NCBI View Article : Google Scholar
|
30
|
Zhou J, Zhang C, Zhou B and Jiang D:
miR-183 modulated cell proliferation and apoptosis in ovarian
cancer through the TGF-β/Smad4 signaling pathway. Int J Mol Med.
43:1734–1746. 2019.PubMed/NCBI View Article : Google Scholar
|
31
|
Kanitz A, Imig J, Dziunycz PJ, Primorac A,
Galgano A, Hofbauer GF, Gerber AP and Detmar M: The expression
levels of MicroRNA-361-5p and its target VEGFA are inversely
correlated in human cutaneous squamous cell carcinoma. PLoS One.
7(e49568)2012.PubMed/NCBI View Article : Google Scholar
|
32
|
Liu D, Tao T, Xu B, Chen S, Liu C, Zhang
L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a
tumor suppressor in prostate cancer by targeting signal transducer
and activator of transcription-6 (STAT6). Biochem Biophys Res
Commun. 445:151–156. 2014.PubMed/NCBI View Article : Google Scholar
|
33
|
Häcker H, Redecke V, Blagoev B,
Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Häcker
G, et al: Specificity in Toll-like receptor signalling through
distinct effector functions of TRAF3 and TRAF6. Nature.
439:204–207. 2006.PubMed/NCBI View Article : Google Scholar
|
34
|
Oganesyan G, Saha SK, Guo B, He JQ,
Shahangian A, Zarnegar B, Perry A and Cheng G: Critical role of
TRAF3 in the Toll-like receptor-dependent and -independent
antiviral response. Nature. 439:208–211. 2006.PubMed/NCBI View Article : Google Scholar
|
35
|
Xie P: TRAF molecules in cell signaling
and in human diseases. J Mol Signal. 8(7)2013.PubMed/NCBI View Article : Google Scholar
|
36
|
Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS,
Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene
in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol
Sci. 22:5156–5164. 2018.PubMed/NCBI View Article : Google Scholar
|